| abstract |
The present invention relates to a process to perform a molecular risk assessment (MRA) upon a sample suspected to contain an enterohemorrhagic Escherichia coli (EHEC), comprising the steps: contacting said sample or DNA isolated therefrom with a pair of primers derived from the following target genes stx1 , stx2 , eae and/or espk ; wherein the process is characterised in that if amplification products are detected for each of the target genes in the first step, in a second step said sample or DNA isolated therefrom is contacted with a pair of primers derived from the following target genes nleB , nleH1-2 , nleE , ent/espL2 , eae subtypes γ, β, ε and θ and the target genes rfbE (0157), wbdl (0111), wzx (026); ihp1 (0145), wzx (0103); and detecting the presence or the absence of an amplification product for each of the target genes. |